You are arguing inconsistently. Older age was actually one of the statistically strongest comparisons against ECA for DCVax-l. Older patients also had 10% survival at ten years. Significant residual disease is just that, measurable tumor left behind. Over 10% five year survival in patients not getting measurable tumor cleared during surgery is a dramatic finding. Your critique to the contrary does not hold water.
Market Data 
Markets 
AI
